Biolytx pharmaceuticals
WebBiolytx Pharmaceuticals has raised a total of $1.1M in funding over 2 rounds. Their latest funding was raised on Nov 6, 2015 from a Seed round. Biolytx Pharmaceuticals is funded by 2 investors. i2i, Inc. and i2E are the most recent investors. WebJan 28, 2024 · 2.1.1 Drug manufacturers - Larger/pharmaceutical 2.1.2 Drug manufacturers - Generic ... Biolytx Pharmaceuticals ; Biosergen ; BioVersys GmbH ; C3J Therapeutics, Inc ; Centauri Therapeutics Ltd ;
Biolytx pharmaceuticals
Did you know?
WebAug 28, 2024 · Biolytx Pharmaceuticals Corp ; Bioversys AG ; Centauri Therapeutics Ltd ; Clarametyx Biosciences Inc ; Cumberland Pharmaceuticals Inc ; CytaCoat AB ; Destiny Pharma PLC ; Dong-A Socio Holdings Co ... WebBiolytx Pharmaceuticals Follow Following Location: USA. Founded in 2005. Private Company " Biolytx is an emerging drug development company confronting the crisis in …
WebBiolytx Pharmaceuticals Follow Following Location: USA. Founded in 2005. Private Company " Biolytx is an emerging drug development company confronting the crisis in antibiotic (AB) drug resistance through the advancement of a suite ... WebMar 31, 2024 · Biolytx Pharmaceuticals Corp. Bioversys AG. Cellular Biomedicine Group Inc. Centauri Therapeutics Ltd. Clarametyx Biosciences Inc. ContraFect Corp. Cumberland Pharmaceuticals Inc. CytaCoat AB. Destiny Pharma Plc. Dong-A Socio Holdings Co Ltd. Eldec Pharmaceuticals Inc. Entasis Therapeutics Holdings Inc.
WebBiolytx is an emerging drug development company confronting the crisis in antibiotic (AB) drug resistance through the advancement of a suite of antimicrobial peptide drug … WebFounded in 2005 by H. Anne Pereira, Ph.D., and William A. Hagstrom, Biolytx is a pharmaceutical technology company developing a novel antibiotic peptide for potential …
WebDr. Pereira is the holder of 15 US patents and 4 foreign patents licensed to Biolytx. She was named a Fellow of the National Academy of Inventors in 2015 for her highly prolific spirit of innovation in creating or facilitating …
WebBiolytx Pharmaceuticals, Oklahoma City. Seed Fund II – $170,000. Biolytx is developing a class of novel antibiotic peptides for use in treatments of ophthalmic wound care and serious hospital-acquired infections. www.biolytx.com [/vc_column_text] [vc_column_text] Clear River Enviro, Edmond. Seed Fund II – $375,000. how many immigration judges are thereWebApr 30, 2016 · April 26, 2016 – Excerpt from NewsOk: “Through an association with William Hagstrom of Alpha Bio Partners, Branch became acquainted with OU professor Anne Pereira, Ph.D. Pereira had co-founded Biolytx Pharmaceuticals with Hagstrom based on her groundbreaking work in developing peptides that kill antibiotic resistant bacteria.” howard charles partnerWebBiolytx Pharmaceuticals Corp. is based on technology developed by Dr. Anne Pereira at the OU Health Sciences Center. Its core technology is development of a novel antibiotic … howard charles kirby quebecWebApr 12, 2024 · 4.2.22 Biolytx Pharmaceuticals 4.2.23 AntibioTx 4.2.24 Xellia Pharmaceuticals 4.2.25 Paratek Pharmaceuticals 4.2.26 Synereca Pharmaceuticals 4.2.27 Allecra Therapeutics 4.2.28 Fixed Phage howard chapel methodist churchWebJan 26, 2024 · Biolytx Pharmaceuticals Biosergen BioVersys GmbH C3J Therapeutics, Inc Centauri Therapeutics Ltd Cipla Combioxin SA Contrafect Corporation Da Volterra Debiopharm International SA howard chapel missionary baptist churchWebBiolytx Pharmaceuticals is a pharmaceutical technology company developed by Dr. Anne Pereira and the University of Oklahoma Health Sciences Center. Still in the pre-clinical … howard changs dallasWebThe lead professional representing IDSC with respect to Biolytx drug development activities is John Domagala, Ph.D., who has over forty years of drug development experience.Dr. Domagala graduated in 1973 from the University of Detroit with a B.S. in Chemistry and in 1977 was conferred a Ph.D. in Organic Chemistry from Wayne State University.He ... howard chapman newcastle